Literature DB >> 1858029

Pentoxifylline suppression of tumor necrosis factor gene transcription.

G M Doherty1, J C Jensen, H R Alexander, C M Buresh, J A Norton.   

Abstract

Pentoxifylline decreases lung injury after intravenous endotoxin; the mechanism is unknown. Tumor necrosis factor-alpha (TNF) is secreted by macrophages in response to endotoxin and mediates some of the toxicity of endotoxin. This study investigates the effects of pentoxifylline on endotoxin-stimulated TNF production in vitro and in vivo. Pentoxifylline concentrations of 100 and 1000 micrograms/ml inhibited TNF production by murine adherent peritoneal exudate cells incubated with endotoxin 1 microgram/ml. Similarly, pentoxifylline at 100 and 1000 micrograms/ml decreased the number of available TNF messenger RNA transcripts in peritoneal exudate cells assessed by Northern blot. Pentoxifylline had no effect on TNF mRNA stability, but appeared to act by inhibiting the rate of TNF mRNA production (transcription). In murine in vivo experiments at each dose of endotoxin administered from 0.01 to 30 mg/kg, pentoxifylline treatment significantly reduced serum TNF levels, suggesting a favorable shift of the endotoxin dose-response curve. Expression of murine TNF gene in the livers of these animals showed fewer TNF transcripts in the pentoxifylline-treated animals compared to controls. Pentoxifylline inhibited endotoxin-induced TNF production both in vivo and in vitro and exerted this control by inhibiting endotoxin-induced transcription of the TNF gene. This study suggests that pentoxifylline may ameliorate endotoxic shock by decreasing macrophage TNF production.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1858029

Source DB:  PubMed          Journal:  Surgery        ISSN: 0039-6060            Impact factor:   3.982


  63 in total

1.  Adjunctive Therapies for Sepsis and Septic Shock.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-08       Impact factor: 3.725

Review 2.  Inflammation and diabetic nephropathy.

Authors:  Carmen Mora; Juan F Navarro
Journal:  Curr Diab Rep       Date:  2006-12       Impact factor: 4.810

Review 3.  The role of inflammation as a pathogenic factor in the development of renal disease in diabetes.

Authors:  Carmen Mora; Juan F Navarro
Journal:  Curr Diab Rep       Date:  2005-12       Impact factor: 4.810

4.  Disrupted NF- kappa B activation after partial hepatectomy does not impair hepatocyte proliferation in rats.

Authors:  Stéphanie Laurent; Yves Horsmans; Peter Stärkel; Isabelle Leclercq; Christine Sempoux; Luc Lambotte
Journal:  World J Gastroenterol       Date:  2005-12-14       Impact factor: 5.742

5.  Pentoxifylline inhibits interleukin-2-induced toxicity in C57BL/6 mice but preserves antitumor efficacy.

Authors:  M J Edwards; B T Heniford; E A Klar; K W Doak; F N Miller
Journal:  J Clin Invest       Date:  1992-08       Impact factor: 14.808

6.  Pentoxifylline does not improve outcome in a murine model for the multiple-organ dysfunction syndrome.

Authors:  T J H Volman; R J A Goris; T Hendriks
Journal:  Intensive Care Med       Date:  2005-02-15       Impact factor: 17.440

7.  Influence of pentoxifylline on cytokine levels and inflammatory parameters in septic shock.

Authors:  T Staudinger; E Presterl; W Graninger; G J Locker; S Knapp; K Laczika; G Klappacher; B Stoiser; A Wagner; P Tesinsky; H Kordova; M Frass
Journal:  Intensive Care Med       Date:  1996-09       Impact factor: 17.440

Review 8.  Therapeutic options for old world cutaneous leishmaniasis and new world cutaneous and mucocutaneous leishmaniasis.

Authors:  Begoña Monge-Maillo; Rogelio López-Vélez
Journal:  Drugs       Date:  2013-11       Impact factor: 9.546

9.  IgG1 antimycobacterial antibodies can reverse the inhibitory effect of pentoxifylline on tumour necrosis factor alpha (TNF-alpha) secreted by mycobacterial antigen-stimulated adherent cells.

Authors:  S M Thakurdas; Z Hasan; R Hussain
Journal:  Clin Exp Immunol       Date:  2004-05       Impact factor: 4.330

10.  Regulation of endothelial VCAM-1 expression in murine cardiac grafts. Expression of allograft endothelial VCAM-1 can be manipulated with antagonist of IFN-alpha or IL-4 and is not required for allograft rejection.

Authors:  S D Bergese; E H Huang; R P Pelletier; M B Widmer; R M Ferguson; C G Orosz
Journal:  Am J Pathol       Date:  1995-07       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.